Dimethyl fumarate Neuraxpharm यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Mylan यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

dimethyl fumarate mylan

mylan ireland limited - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Polpharma यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Teva यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dimetylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressive - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Accord यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dimetylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressive - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Tecfidera यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

tecfidera

biogen netherlands b.v. - dimetylfumarat - multippel sklerose - immunsuppressive - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).